A5103117875- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Cardiac and Coronary Surgery Techniques
- Neutropenia and Cancer Infections
- Gastric Cancer Management and Outcomes
- Tracheal and airway disorders
- Cardiac, Anesthesia and Surgical Outcomes
- Peptidase Inhibition and Analysis
- Cancer Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Brain Metastases and Treatment
- Medical Imaging and Pathology Studies
- Intracranial Aneurysms: Treatment and Complications
- Cardiac Valve Diseases and Treatments
- Palliative Care and End-of-Life Issues
Yokohama Municipal Citizen's Hospital
2016-2025
Takamatsu Red Cross Hospital
2018
Saga-Ken Medical Centre Koseikan
2010-2017
Saga University
2004-2017
Japan Fisheries Research and Education Agency
1997-2016
National Cancer Center Hospital East
1994-2015
Niigata Cancer Center Hospital
2006-2015
Osaka City General Hospital
2015
Japan Clinical Cancer Research Organization
2014
Nagoya University
2014
This multicenter, phase II study was conducted to evaluate the activity of amrubicin, a topoisomerase inhibitor, against refractory or relapsed small-cell lung cancer (SCLC).SCLC patients with measurable disease who had been treated previously at least one platinum-based chemotherapy regimen and an Eastern Cooperative Oncology Group performance status 0 2 were eligible. Two groups selected: experienced first-line treatment failure less than 60 days from discontinuation (refractory group),...
We compared the efficacy and safety of a carboplatin plus etoposide regimen (CE) vs split doses cisplatin (SPE) in elderly or poor-risk patients with extensive disease small-cell lung cancer (ED-SCLC). Eligibility criteria included: untreated ED-SCLC; age ⩾70 performance status 0–2, <70 PS 3. The CE arm received area under curve five intravenously (IV) on day 1 80 mg m−2 IV days 1–3. SPE 25 1–3 Both regimens were given granulocyte colony-stimulating factor support 21–28 cycle for four...
This multicenter, randomized, open-label, phase II study (JO19907) compared the efficacy and safety of first-line carboplatin-paclitaxel (CP) alone with bevacizumab-CP in Japanese patients advanced non-squamous non-small-cell lung cancer (NSCLC).Chemonaïve stage IIIB, IV or recurrent NSCLC were eligible for participation. Patients randomly assigned a 2:1 ratio to receive CP alone. Chemotherapy was repeated up 6 cycles until disease progression unacceptable toxicity. Bevacizumab recipients...
Purpose This phase III trial aimed to confirm the superiority of weekly docetaxel and cisplatin over monotherapy in elderly patients with advanced non–small-cell lung cancer (NSCLC). Patients Methods Chemotherapy-naïve stage III, IV, or recurrent NSCLC age ≥ 70 years a performance status 0 1 who were considered unsuitable for bolus administration randomly assigned receive 60 mg/m 2 on day 1, every 3 weeks, 20 plus 25 days 8, 15, 4 weeks. The primary end point was overall survival (OS)....
PURPOSE To evaluate the efficacy of pemetrexed plus cisplatin versus vinorelbine as postoperative adjuvant chemotherapy in patients with pathologic stage II-IIIA nonsquamous non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS We performed a randomized, open-label, phase III study at 50 institutions within 7 clinical groups Japan. Patients completely resected (TNM 7th edition) NSCLC were randomly assigned to receive either (500 mg/m 2 , day 1) (75 or (25 days 1 and 8) (80 stratification...
Abstract Introduction The systemic immune-inflammation index (SII) has emerged as a promising prognostic marker in various malignancies. However, its significance patients with small-cell lung cancer (SCLC) treated immune checkpoint inhibitors (ICIs) remains unclear. In this study, we evaluated the impact of SII SCLC after ICI use. Methods Of 62 who received chemoimmunotherapy at our institution between September 2019 and July 2024, retrospectively analyzed 36 subsequently maintenance...
Platinum-based two-drug combination chemotherapy has been standard of care for patients with advanced nonsmall-cell lung cancer (NSCLC). The primary aim was to compare overall survival (OS) NSCLC between the two regimens. Secondary end points included progression-free (PFS), response, safety, and quality life (QoL).Patients previously untreated stage IIIB or IV NSCLC, an Eastern Cooperative Oncology Group performance status 0-1 adequate organ function were randomized receive either oral S-1...
Few clinical trials have been specifically designed for elderly patients with advanced non-small cell lung cancer (NSCLC), and the anticipated increase in number of such has prompted a search new treatment options that provide greater palliative benefit.To determine whether carboplatin plus pemetrexed followed by maintenance is noninferior compared docetaxel monotherapy regard to overall survival (OS) nonsquamous NSCLC.This open-label, multicenter, noninferiority phase 3 randomized trial was...
Abstract The prognosis of non‐small‐cell lung cancer (NSCLC) patients with interstitial disease (ILD) is poor, and 5%‐20% those receiving chemotherapy experience ILD exacerbation. To evaluate the safety efficacy nab‐paclitaxel plus carboplatin for NSCLC ILD, we undertook a multicenter phase II study. Chemotherapy‐naïve advanced mild or moderate received (100 mg/m 2 , days 1, 8, 15) (area under curve = 6, day 1) every 3 weeks 4 cycles (maximum, 6 cycles). Interstitial diseases were diagnosed...
Rationale: A fatal acute exacerbation (AE) occasionally develops during chemotherapy for small cell lung cancer (SCLC) with comorbid idiopathic pulmonary fibrosis (IPF).Objectives: This study aimed to assess the safety and efficacy of carboplatin, etoposide, nintedanib combination therapy unresectable SCLC IPF.Methods: The NEXT-SHIP is a multicenter, single-arm, phase 2 trial IPF (Japan Registry Clinical Trials registry number jRCTs031190119). patients received (150 mg twice daily). primary...
Abstract Hemangioblastomas are central nervous system (CNS) tumors of unknown histogenesis, which can occur sporadically or in von Hippel-Lindau disease. composed neoplastic “stromal” cells origin, accompanied by intensive reactive angiogenesis. Failure to specify the cytologic origin stromal cell has precluded development nonsurgical therapies and limits understanding its basic biology. We report that express proteins (Scl, brachyury, Csf-1R, Gata-1, Flk-1, Tie-2) characterize embryonic...
The G8 questionnaire is a quick and easy-to-use screening tool. Several studies reported that the had high sensitivity for predicting abnormalities in full comprehensive geriatric assessment predicted functional decline survival elderly cancer patients. present study aimed to evaluate role of clinical outcomes overall (OS) patients with lung cancer, who received chemotherapy or chemoradiotherapy. data 101 aged ≥70 years, were hospitalized between September 2011 August 2014, analyzed. Of...
Although the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for EGFR gene mutation-positive non-small cell lung cancer is well established, optimal dosing remains to be especially in elderly or frail patients.To investigate and safety low-dose erlotinib patients with cancer.Single-arm phase 2 trial Southwest Oncology Group (SWOG) 2-stage design that enrolled from 21 Japanese institutions after meeting inclusion criteria. Chemotherapy-naive EGFR-activating who were...
Abstract Purpose: Concurrent chemoradiotherapy (CCRT) followed by durvalumab consolidation for up to 12 months is the standard of care patients with unresectable stage III non–small cell lung cancer (NSCLC). However, exactly when initiate therapy after chemoradiation completion remains unknown. We evaluated efficacy and safety durvalumab, administered immediately CCRT completion, NSCLC. Patients Methods: This study was a prospective, single-arm, open-label phase II clinical trial. without...
PURPOSE: The target area under the plasma-concentration-versus-time curve (AUC)–based dosing of carboplatin using Calvert's formula is expected to result in more acceptable toxicity and greater efficacy elderly patients with small-cell lung cancer (SCLC) than body surface area–based strategy. This phase II study was designed determine based on plus standard dose intravenous etoposide for SCLC. PATIENTS AND METHODS: Carboplatin, dosed a AUC 5 × (24-hour creatinine clearance + 25), given...
Between 1978 and 1990, 51 cases of pericardial effusion secondary to lung cancer were treated at the National Cancer Center Hospital by creating a window, using subxiphoid approach, that was connected water-sealed drainage system.Most patients had advanced disease, such as distant metastasis (76%), pleural (88%), clinical Stage N2 or N3 disease (98%). Forty-five cardiac tamponade, six no symptoms attributable effusion. Cardiac tamponade initial manifestation in only 3 patients; it late 48....